Talis Biomedical Corp (TLIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 59,867 | 70,337 | 76,732 | 87,996 | 99,210 |
| Receivables | N/A | 6 | 50 | 5 | 532 |
| TOTAL | $63,601 | $71,170 | $77,683 | $89,532 | $101,965 |
| Non-Current Assets | |||||
| PPE Net | 425 | 1,628 | 3,030 | 3,332 | 3,539 |
| Other Non-Current Assets | 8,673 | 9,696 | 13,961 | 14,364 | 17,572 |
| TOTAL | $9,098 | $11,324 | $16,991 | $17,696 | $21,111 |
| Total Assets | $72,699 | $82,494 | $94,674 | $107,228 | $123,076 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,790 | 3,619 | 1,339 | 2,697 | 2,491 |
| Accrued Expenses | 1,483 | 2,950 | 4,551 | 2,892 | 4,035 |
| TOTAL | $8,196 | $9,471 | $8,772 | $8,450 | $9,262 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 15,877 | 16,339 | 16,786 | 17,222 | 17,648 |
| TOTAL | $15,877 | $16,339 | $16,786 | $17,222 | $17,648 |
| Total Liabilities | $24,073 | $25,810 | $25,558 | $25,672 | $26,910 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,823 | 1,822 | 1,822 | 1,821 | 1,819 |
| Retained earnings | -561,845 | -552,996 | -539,961 | -526,501 | -510,819 |
| Other shareholders' equity | 3 | 3 | 3 | 3 | 3 |
| TOTAL | $48,626 | $56,684 | $69,116 | $81,556 | $96,166 |
| Total Liabilities And Equity | $72,699 | $82,494 | $94,674 | $107,228 | $123,076 |